Loading organizations...
Loading organizations...
Fuse Diagnostics: Develops rapid, instrument-free diagnostic tests for pathogens in clinical, industrial, food, water, and veterinary sectors.
Fuse Diagnostics is a biotechnology company that develops rapid, low-cost, and instrument-free diagnostic tests for pathogen detection across clinical, industrial, food, water, and veterinary applications. The organization utilizes proprietary flip and Apex platforms combined with ultra-rapid amplification chemistries to deliver laboratory-quality results at the point of need in under 10 minutes. To commercialize these diagnostic products, the startup has successfully raised £1.6 million in an oversubscribed seed funding round backed by private angel investors and the government agency Innovate UK. Operating as a CARB-X portfolio company, the firm develops specialized healthcare solutions, including the Apex CT/NG test aimed at addressing critical gaps in testing for antibiotic resistance. Fuse Diagnostics was established in 2022 by Harry Lamble and Ralph Lamble, who previously built the molecular diagnostic firm Sense Biodetection prior to its acquisition by Sherlock Biosciences.
Fuse Diagnostics has raised $2.0M across 1 funding round.
Fuse Diagnostics has raised $2.0M in total across 1 funding round.
Fuse Diagnostics has raised $2.0M in total across 1 funding round.
Fuse Diagnostics's investors include Innovate UK.
Fuse Diagnostics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 28, 2024 | $2.0M Seed | Innovate UK |